A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants
Clinical trial NCT05140096 · COMPLETED
Trial details
- NCT number
- NCT05140096
- Sponsor
- Acerta Pharma BV
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-01-03
- Primary completion
- 2020-04-15
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.